Pfizer and Clear Creek Bio will collaborate to research SARS-CoV-2 papain-like protease (PLpro) inhibitors, with the aim of developing an oral treatment for COVID-19. It’s still in its discovery phase, but if successful, Pfizer said it will pay the biotech company “an undisclosed upfront payment,” milestone payments and royalties, according to a Dec. 6 news release.
The enzyme PLpro is “a unique viral protease that cleaves important host regulators of innate immunity such as ISG15, resulting in dampened antiviral immune mechanisms,” according to Clear Creek Bio’s website.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
